Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Rasburicase Articles

ASH hears strong data on Novartis

22 December 2008

Sanofi's Elitek reduces PUA more than allopurinol

15 December 2008

Sanofi-Aventis sales in Japan to double from 2005 to 2009

24 March 2008

53.7% US sales leap boosts Sanofi-Synthelabo

27 January 2003

Declining drug launches in Europe drives imperative for sustained lifecycle pricing

22 July 2002

Sanofi's Elitek approved in USA

22 July 2002

France's Sanofi-Synthelabo announces New York stock listing

8 July 2002

Tally of NCEs in 2001 lends credence to talk of R&D productivity

21 January 2002

Stock Commentary - Europe

14 June 2001

Sanofi-Synthelabo's Fasturtec launched in the UK, Germany

11 June 2001

Stock Commentary - Europe

11 April 2001

Stock Commentary - Europe

5 April 2001

New Sanofi-Synthelabo cancer drug OKed in EU

30 March 2001

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS